Table 2.

Viral inhibition of RIG-I and MDA5. Different viral antagonistic strategies are detailed, including information on the virus and the specific protein responsible for RLR antagonism.

RIG-I
Inhibition of ATPase activity	Ebola	VP35	Luthra et al., 2013 [134]
	MERS-CoV	4a	Siu et al., 2014 [140]
Sequestration	SARS-CoV	M Protein	Siu et al., 2009 [141]
	SARS-CoV	ORF3b	Kopecky-Bromberg et al., 2007 [143]
	SARS-CoV	ORF6	Freundt et al., 2009 [142]
	NW Arenavirus	Z protein	Fan et al., 2010 [146]
	hMPV	G protein	Bao et al., 2008 [148]; Bao et al., 2013 [147]
	RSV	N Protein	Lifland et al., 2012 [149]
	RSV	NS1/NS2	Goswami et al., 2013 [151]
Cleavage	Poliovirus	3Cpro	Barral et al., 2009 [159]
	Rhinovirus
	Echovirus
	EMCV
MDA5
Inhibition of ATPase activity	Paramyxovirus	V protein	Motz et al., 2013 [132]; Rodriguez and Horvath 2013 [130]
	MERS-CoV	4a	Siu et al., 2014 [140]
Sequestration	RSV	N Protein	Lifland et al., 2012 [149]
Cleavage	Poliovirus		Barral et al., 2007 [158]
	EV71	2Apro	Feng et al., 2014 [163]